dpp-4_inhibitors DPP-4 Inhibitors Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)
Emerging nanocarrier platforms aim to improve drug bioavailability and target specificity ( Naqvi et al., 2020
Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, Dodig G, Rucman R, et al
At Yale, people can be seen by dietitians, social workers, psychologists, psychiatrists, movement disorder specialists, adult and pediatric liver specialists, and liver transplant experts as necessary
While multiple treatments are available, very few directly address the central INSR/IRS pathway
The elderly: As we age, the ability to digest and absorb Vitamin B12 may decrease
